Recurrence of atrial fibrillation after switching from brand to generic atenolol

Luca Gallelli; Francesca Maida; Orietta Staltari; Pierandrea Rende; Emilio Russo; Benedetto Caroleo; Giovambattista De Sarro

doi:10.4103/0976-500X.149146

Recurrence of atrial fibrillation after switching from brand to generic atenolol

J Pharmacol Pharmacother. 2015 Jan-Mar;6(1):39-41. doi: 10.4103/0976-500X.149146.

Authors

Luca Gallelli¹, Francesca Maida¹, Orietta Staltari¹, Pierandrea Rende¹, Emilio Russo¹, Benedetto Caroleo¹, Giovambattista De Sarro¹

Affiliation

¹ Department of Health Science, University of Catanzaro, Catanzaro, Italy.

Abstract

Beta blockers are the initial treatment for rate control of supraventricular tachyarrhythmia in patients without a history of myocardial infarction or left ventricular dysfunction. In this article we report the recurrence of atrial fibrillation after switching to the generic formulation of atenolol.

Keywords: Atenolol; atrial fibrillation; brand drug; clinical ineffectiveness; generic drug.

Publication types

Case Reports